CME Group Inc. (NASDAQ:CME) Position Reduced by Glenmede Trust Co. NA

Glenmede Trust Co. NA lessened its position in CME Group Inc. (NASDAQ:CME) by 8.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 102,513 shares of the financial services provider’s stock after selling 9,555 shares during the quarter. Glenmede Trust Co. NA’s holdings in CME Group were worth $22,619,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Truvestments Capital LLC acquired a new stake in shares of CME Group during the third quarter worth approximately $26,000. Y.D. More Investments Ltd purchased a new stake in shares of CME Group during the 2nd quarter worth about $36,000. McClarren Financial Advisors Inc. lifted its holdings in shares of CME Group by 66.1% during the 2nd quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider’s stock valued at $39,000 after buying an additional 78 shares during the last quarter. Asset Dedication LLC grew its stake in shares of CME Group by 515.2% in the 2nd quarter. Asset Dedication LLC now owns 203 shares of the financial services provider’s stock valued at $40,000 after buying an additional 170 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. increased its holdings in CME Group by 62.2% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 193 shares of the financial services provider’s stock worth $43,000 after buying an additional 74 shares during the last quarter. Institutional investors and hedge funds own 87.75% of the company’s stock.

CME Group Stock Up 1.3 %

NASDAQ CME opened at $237.33 on Thursday. CME Group Inc. has a twelve month low of $190.70 and a twelve month high of $238.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.02 and a current ratio of 1.02. The stock has a market cap of $85.52 billion, a PE ratio of 24.96, a PEG ratio of 5.29 and a beta of 0.55. The firm has a 50-day simple moving average of $224.60 and a 200 day simple moving average of $211.56.

CME Group (NASDAQ:CME) last announced its quarterly earnings data on Wednesday, October 23rd. The financial services provider reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.03. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.59 billion. CME Group had a return on equity of 13.39% and a net margin of 57.34%. CME Group’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.25 EPS. On average, research analysts forecast that CME Group Inc. will post 10.22 EPS for the current year.

CME Group Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 27th. Stockholders of record on Monday, December 9th will be given a dividend of $1.15 per share. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.60 annualized dividend and a dividend yield of 1.94%. CME Group’s dividend payout ratio (DPR) is currently 48.37%.

Insider Activity at CME Group

In related news, insider Timothy Francis Mccourt sold 1,374 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $227.12, for a total transaction of $312,062.88. Following the completion of the sale, the insider now owns 7,275 shares in the company, valued at $1,652,298. This trade represents a 15.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Martin J. Gepsman sold 400 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $222.92, for a total transaction of $89,168.00. Following the completion of the transaction, the director now owns 25,067 shares in the company, valued at approximately $5,587,935.64. This trade represents a 1.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,621 shares of company stock valued at $3,441,063 over the last quarter. 0.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CME. Piper Sandler increased their price target on shares of CME Group from $240.00 to $250.00 and gave the stock an “overweight” rating in a research note on Monday, October 28th. Redburn Atlantic lowered CME Group from a “buy” rating to a “neutral” rating and set a $244.00 target price on the stock. in a report on Tuesday, October 8th. Citigroup boosted their price target on CME Group from $250.00 to $255.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. The Goldman Sachs Group upped their price target on CME Group from $195.00 to $198.00 and gave the stock a “sell” rating in a research note on Thursday, October 3rd. Finally, TD Cowen started coverage on CME Group in a research report on Thursday, September 26th. They set a “hold” rating and a $221.00 target price for the company. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $224.47.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.